Delivery by

DailyUpdates by e-mail - the publication tracker for the drug discovery community

Todays Headlines from across the DailyUpdates network

  • Breaking News (from DailyUpdates-Metabolic Disorders): Shinogi announce phase 2 data on anorectic agent S-2367: The prevalence of obesity has increased by 61% in the US during the period 1991-2001. According to Datamonitor 127m people suffered from the disease in the seven major markets in 2003. Obesity is an active area of research and development and our recent feature from Datamonitor (Obesity - commercial opportunites and therapeutic pipeline analysis) discusses 22 key compounds in Phase I development or above. Neuropeptide Y (NPY) a potent orexigenic agent that acts through five different receptor subtypes represents a therapeutic target for anorectic agents.  The predominant NPY orexigenic receptors are NPY-Y1 and NPY-Y5, while activation of the presynaptic Y2 receptor limits the release of NPY thus reducing food intake.  One peptide from the NPY family, Peptide YY (PYY) has received considerable attention as it an endogenous Y2 receptor agonist in the arcuate nucleus which acts to reduce appetite.  Thus Nastech Pharmaceuticals and Amylin are both developing formulations of PYY 3-36 which are currently in phase 2 and phase 1 development respectively.  In addition 7TM Pharma have recently announced positive results from its phase I/II study of TM30338, a dual Y2-Y4 receptor agonist.  Today’s featured press release from Shionogi & Co announces top-line efficacy results from a Phase IIa proof-of-concept trial with S-2367 which, uniquely, blocks NPY binding to Y5 receptors [Source:Shionogi]
  • Featured Journal Article (from DailyUpdates-Oncology): Clinical data on Sutent (Sunitinib) as a treatment of renal cell carcinoma: A meager 20% of metastatic renal cell carcinoma (RCC) tumors respond to standard cytokine therapy, thus rendering 80% of advanced RCC patients without any effective treatment. Further, with up to 50% of stage one to three patients relapsing following nephrectomy and an increasing incidence of this disease, RCC represents a largely unmet disease.  Nexavar (Bayer; approved in the US in 2005) and Sutent (Sunitinib; Pfizer; approved in the US in 2006), both indicated for metastatic RCC, look set to compete well to the end of the decade. With Nexavar's first to market advantage and Sutent's purported superior efficacy, revenue margins will lie extremely close. Datamonitor forecasts Nexavar's 2010 revenues will reach $122 million and Sutent's $179 million (Renal Cell Carcinoma - Novel Targeted Treatments).  Today’s featured paper report data from an open-label, single-arm, multicenter clinical trial of Sutent monotherapy in patients with RCC [JAMA. 2006 Jun 7;295(21):2516-24]

Advertize in this space and reach out to the drug development sector


Pharmaceutical and biotech jobs page If this icon appears after any of our listed articles, the author is able to provide reprints. Articles denoted by an Licensing Op. icon describe data relevant to licensing opportunities. The report icon, , links through to full analyses relating to pharmaceutical/market developments relating to this work

Today's Jobs
The Jobs database now has 815 jobs. A selection of the latest jobs can be found below:

Clinician
UK
Featured job  from RDL Scientific Limited

Senior Scientist Stem Cell Immunology
San Francisco

Featured job  from CyberScientific

Opportunities in Programme Management - Oncology & CNS
United Kingdom
Featured job  from RSA Pharmarecruit

DIRECTOR OF PHARMACOVIGILANCE
United Kingdom
Featured job  from Executive Facilities


Selection of latest jobs:

Drug Safety
Germany
Research Chemist
UK
Research Scientist
UK
Global Clinical Operations Associate for premier Pharma
UK
Scientist Protein Production
Belgium
DATA MANAGER
Netherlands
Research Scientist Cell Culture
UK
Research Associate, Antibody Biology
UK

More

Search our jobs database, submit your CV/Resume, register for job alerts, or post a vacancy here


Find breaking R&D articles
 Search Tips

Select Disease Area for Search
Oncology
Cancer Immunotherapy
Pain Therapeutics
Psychiatry
Neurodegenerative Disorders
Cardiovascular Disease
Metabolic Diseases
Inflammation
Infectious Diseases
Genitourinary Tract Disorders
Technology
Other searches
News
PharmaReports

What is R&DBase?
Breaking reports&news by mail

Powered by LeadDiscovery

Headline Article(s)

JAMA. 2006 Jun 7;295(21):2516-24. Sunitinib in patients with metastatic renal cell carcinoma. Renal Cell Carcinoma - Novel Targeted Treatments

Today's journal articles

Mol Cancer Ther. 2006 Apr;5(4):1029-40. Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors. Drug Delivery in Cancer - technologies, markets and companies

New PharmaReports loaded today:

Bioorg Med Chem. 2006 May 2; [Epub ahead of print] 5-Alkylated thiazolidinones as follicle-stimulating hormone (FSH) receptor agonists. Endometriosis - Growing the Patient Population is Key to Unlocking the Market's Commercial Potential

Bioorg Med Chem. 2006 Apr 4; [Epub ahead of print] Evaluation of mismatch-binding ligands as inhibitors for Rev-RRE interaction.

Vaccine. 2006 May 15; [Epub ahead of print] Inhalative vaccination with pneumococcal polysaccharide in patients with chronic obstructive pulmonary disease. The Therapeutic and Prophylactic Vaccine Market The World Market for Vaccines Vaccines - Reaching Adulthood

Am J Transplant. 2006;6(5 Pt 2):1111-31. Immunosuppression: evolution in practice and trends, 1994-2004. Autoimmune Disorders & Transplant Rejection - Opportunities for the Drug Development Sector

Bioorg Med Chem Lett. 2006 Jun 15;16(12):3150-5. Epub 2006 Apr 5. Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity.

Mol Cancer Res. 2006 Apr;4(4):235-46. Activin receptor-like kinase 7 induces apoptosis through up-regulation of Bax and down-regulation of Xiap in normal and malignant ovarian epithelial cell lines.

Arch Pharm (Weinheim). 2006 May;339(5):242-9. C-(2-chloroquinoline-3-yl)-N-phenyl nitrone: new synthetic antioxidant inhibits proliferation and induces apoptosis of breast carcinoma MCF-7 cells. Breast Cancer - Changing Treatment Paradigms for Local and Locally Advanced Breast Cancer Breast Cancer - Complex Combinations of Old and New

Clin Ther. 2006 Feb;28(2):266-79. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Commercial Insight: ADHD Pipeline Insight: ADHD

Bioorg Med Chem Lett. 2006 Jun 15;16(12):3105-10. Epub 2006 Apr 17. Carboxy derivatized glucosamine is a potent inhibitor of matrix metalloproteinase-9 in HT1080 cells.

Bioorg Med Chem Lett. 2006 Jun 15;16(12):3315-8. Epub 2006 Apr 17. Design, synthesis, and evaluation of novel kazusamycin A derivatives as potent antitumor agents.

Br J Anaesth. 2006 Jun;96(6):761-8. Epub 2006 May 4. Antinociceptive effects of tetrodotoxin (TTX) in rodents.

Cancer Res. 2006 Apr 1;66(7):3773-81. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.

Bioorg Med Chem. 2006 Jul 15;14(14):4775-80. Epub 2006 Apr 5. Synthesis of a library of polycationic lipid core dendrimers and their evaluation in the delivery of an oligonucleotide with hVEGF inhibition.

Bioorg Med Chem Lett. 2006 Jun 15;16(12):3310-4. Epub 2006 Apr 4. Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design.

Bioorg Med Chem. 2006 Jul 15;14(14):4775-80. Epub 2006 Apr 5. Synthesis of a library of polycationic lipid core dendrimers and their evaluation in the delivery of an oligonucleotide with hVEGF inhibition.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2216-23. Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer.

Cancer. 2006 Jun 1;106(11):2437-44. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma.

J Immunol. 2006 Apr 15;176(8):4757-65. Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade).

J Immunol. 2006 Apr 15;176(8):4573-80. Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. Cancer Vaccines Cancer Vaccines and Cell Therapies The emerging Cancer Vaccine Market

Life Sci. 2006 May 22;78(26):3043-50. Epub 2006 Apr 4. Antimetastatic activity of Sulforaphane.

Cardiovasc Diabetol. 2006 Apr 7;5:8. Anemia is an independent risk for mortality after acute myocardial infarction in patients with and without diabetes. Commercial Insight: Antidiabetic drugs Diabetes, Metabolic Syndrome & Cardiovascular Disease: Reshaping Tomorrow's Diabetes Market The World Diabetes Market, 2005-2011

Nature. 2006 Jun 15;441(7095):885-9. Epub 2006 Apr 19. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Neurodegenerative Disorders: World Markets 2002-2007 World Neurodegeneratives Disease Markets, 2005-2009

FASEB J. 2006 May;20(7):896-905. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. Autoimmune Disorders & Transplant Rejection - Opportunities for the Drug Development Sector Multiple Sclerosis - How to Find Opportunities in an Unremitting Market

Bioorg Med Chem Lett. 2006 Jun 15;16(12):3162-5. Epub 2006 Apr 17. Benzo[b]thiophene-2-carboxamides and benzo[b]furan-2-carboxamides are potent antagonists of the human H3-receptor.

Diabetes Res Clin Pract. 2006 Apr 4; [Epub ahead of print] A single transplantation of the islets can produce glycemic stability and reduction of basal insulin requirement. Autoimmune Disorders & Transplant Rejection - Opportunities for the Drug Development Sector Commercial Insight: Antidiabetic drugs

Congest Heart Fail. 2006 Mar-Apr;12(2):85-90. Obese patients have lower B-type and atrial natriuretic peptide levels compared with nonobese. Cardiac Marker Diagnostic Tests Markets

Biol Chem. 2006 Apr;387(4):431-6. Role of the kinin B1 receptor in insulin homeostasis and pancreatic islet function. The World Diabetes Market, 2005-2011

J Pharmacol Exp Ther. 2006 Apr 7; [Epub ahead of print] Preventive and Therapeutic Potential of p38{alpha} Selective MAPK Inhibitor in NOD Mice with Type 1 Diabetes. Autoimmune Disorders & Transplant Rejection - Opportunities for the Drug Development Sector

World J Gastroenterol. 2006 May 14;12(18):2876-83. Immune therapy including dendritic cell based therapy in chronic hepatitis B virus infection. Pipeline Insight - Hepatitis B therapeutics

J Clin Invest. 2006 Apr;116(4):1063-70. Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion. Ventricular Fibrillation and Atrial Fibrillation

Haematologica. 2006 Apr;91(4):554-7. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Pipeline Insight - Hepatitis B therapeutics Pipeline Insight: Hematological malignancies-Targeted treatments and immunotherapy infuse new blood

Am J Physiol Heart Circ Physiol. 2006 Apr 7; [Epub ahead of print] Effects of dexamethasone and L-canavanine on the intracellular calcium/contraction relationship of the rat tail artery during septic shock. Sepsis

Infect Immun. 2006 Jun;74(6):3222-31. Human recombinant antibodies against Plasmodium falciparum merozoite surface protein 3 cloned from peripheral blood leukocytes of individuals with immunity to malaria demonstrate antiparasitic properties.

Circulation. 2006 May 9;113(18):2201-10. Epub 2006 May 1. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Chronic and Acute Heart Failure

Clin Cardiol. 2006 Apr;29(4):141-3. Inhibition of sodium-dependent calcium overload to treat myocardial ischemia.

Europace. 2006 May;8(5):341-4. Supraventricular ectopy and recurrence of atrial fibrillation after electrical cardioversion. Atrial Fibrillation: Emerging drug discovery targets and therapeutic candidates Cardiac Rhythm Management Devices World Markets

Biomaterials. 2006 Sep;27(25):4477-83. Epub 2006 May 4. PEGylated albumin-heme as an oxygen-carrying plasma expander: Exchange transfusion into acute anemia rat model. Cancer Market Top 20 Drugs - Supportive Care Grows the Cancer Market

J Cardiovasc Pharmacol. 2006 Apr;47(4):614-20. Amelioration of ischemia/reperfusion-induced myocardial infarction by the 2-alkynyladenosine derivative 2-octynyladenosine (YT-146).

Today's top news story

Shionogi Announces Positive Results From a Phase IIa Study of S-2367, a Novel Neuropeptide Y5 Receptor Antagonist For the Treatment of Obesity

Other news stories featured today
You can also
search our archives for R&D news)

Genoptix Announces FDA Cleared Test to Identify Circulating Tumor Cells

AnorMED Completes Enrollment in Phase III Trial for MOZOBIL

Oncolytics Biotech Begins Patient Enrolment in U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial

Submit your press release or have LeadDiscovery produce a release for you

All of today's news stories updated every 30 minutes


PharmaReports

Click here for our full list of PharmaReports


Free registration for DailyUpdates

Someone you work with could benefit from receiving DailyUpdates Register them now or forward this e-mail and let them register...


Submit your publication to DailyUpdates


  • Subscription to targeted DailyUpdates channels

    • Oncology
    • Cancer Immunotherapy
    • Pain
    • Psychiatric, Addicitve & Sleep Disorders
    • Neurodegenerative & Neuroelectrophysiological Disorders
    • Cardiovascular disease
    • Metabolic & Hormonal disorders
    • Immunology & Inflammation
    • Infectious Diseases
    • Genitourinary Tract Disorders
    • Technology

    Note: Subscription by an increasing number of major pharmaceuticals means that it is possible you already have access to targeted DailyUpdates. Click here to find out if you have access.


    Submit your publication to DailyUpdates


    LeadDiscovery homepage


    Unregister from DailyUpdates